Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05283226 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
A Phase 2 study of Carcinoma and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, sponsored by NATCO Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 13
- Study locations
NCT05283226 is a Phase 2 study of Carcinoma and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma that is actively recruiting participants, run by NATCO Pharma. The registered enrollment target is 21 participants, below the 254-participant average among 29 other Carcinoma trials with a reported enrollment target (92% lower). The trial reports 13 study locations across 10 states.
The verdict
NCT05283226, a Phase 2 study of Carcinoma and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, is actively recruiting participants, sponsored by NATCO Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy. A total of approximately 46 male and female patients will be enrolled. This sample size is based on Simon's 2-stage design with historical control ORR of 30% and a target ORR of 50%.
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG NRC-2694-A
Study Locations (13)
California
- Providence Medical Foundation -Fullerton - Fullerton
- Los Angeles Hematology Oncology Medical Group - Los Angeles
Florida
- Lynn Cancer Center - Boca Raton
- Miami Cancer Center - Miami
Maharashtra
- Daycare Angels under AOH - Mumbai
- Grant Medical Foundation Ruby Hall Clinic - Pune
Kentucky
- Norton Cancer Institute - Downtown - Louisville
Maryland
- University of Maryland Greenebaum Cancer Center - Baltimore
Missouri
- Washington University - Siteman Cancer Center - St Louis
New Hampshire
- Dartmouth Hitchcock Medical Center - Lebanon
Pennsylvania
- Salib Oncology - Easton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-09-30 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05283226
The ClinicalTrials.gov registry entry for NCT05283226 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 254-participant average among 29 other Carcinoma trials with a reported enrollment target (92% lower). The listed sponsor is NATCO Pharma, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.
NCT05283226 reports 13 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Maharashtra.
Frequently Asked Questions
What is clinical trial NCT05283226 about?
NCT05283226 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy". This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy. A total of approximately 46 male and female patients will be enrolled. This sample size is based on Simon's 2-stage design w...
What is the current status of trial NCT05283226?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2022-09-30. Estimated completion is 2027-06-30.
What conditions does trial NCT05283226 study?
This clinical trial studies the following conditions: Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
What interventions are being tested in trial NCT05283226?
The interventions under investigation include: Paclitaxel (DRUG), NRC-2694-A (DRUG).
Who is sponsoring clinical trial NCT05283226?
This trial is sponsored by NATCO Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05283226 being conducted?
This trial has 13 study locations across California, Florida, Kentucky, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
RECRUITING · Phase 2
-
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
RECRUITING · Phase 2
-
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
COMPLETED · Phase 2
-
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
RECRUITING · Early Phase 1
-
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Carcinoma
All registered trials for this condition
Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.